Jordi Casanova from IRB Barcelona wrote an opinion article in EMBO Journal.
The author highlights that scientists should be aware of the limitations of models and categories.
The video series Meet Our Scientists presents Travis Stracker, head of the Genomic Instability and Cancer lab at IRB Barcelona.
The video “Maintaining stability of the genome” highlights the research underway to unravel how cells prevent genomic instability.
A study on breast cancer conducted at IRB Barcelona identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage, which would otherwise cause cell death.
p38 blockage has been shown to increase the death of tumour cells, thus causing tumours to shrink.
The combination of p38 inhibitors with chemotherapeutic drugs (taxanes) strengthens, accelerates or prolongs the antitumour effect in patient-derived tumours grown in mice.
For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.
Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.
Nine scientists at IRB Barcelona form part of EMBO, an organisation that comprises more than 1,800 outstanding researchers from Europe and around the world specialised in molecular biology.
“This will allow me to strengthen interactions with other European researchers, as well as to stay abreast of new ideas, concepts and technologies,” says Aznar Benitah.
BIST has selected 12 winners, among them Guiomar Solanas, Jelena Urosevic and Lidia Mateo.
This programme recognises excellence in research and supports women scientists in their transition to leadership positions.
The study, published in The Journal of Cell Biology, focuses on the development of the sperm tail, the structure that enables sperm cells to swim and is therefore critical for male fertility.
Organizations of the industry, and associations connected to R+D+i express their support towards research, backing the petition of the Severo Ochoa and María de Maeztu alliance (SOMMa) which advocates in favour of the political class acting to clear the administrative problems currently affecting science in Spain.
SOMMa and the organizations supporting this initiative such as IRB Barcelona, represent close to 6,800 businesses, societies, centres and research units, which give employment to more than 500,000 people in Spain, and have an economic activity equivalent to 10,53 % of the gross domestic product.
Sergi Ferrer-Salat, president of the Board of Trustees of the Ferrer Research Foundation, highlighted that the work done by IRB Barcelona scientist, Manuel Serrano, is helping to further our understanding of the relation between ageing and cancer and identify approaches to manipulate this relation to our advantage.
IRB Barcelona scientist, Modesto Orozco has been granted 150,000 euros to optimise and validate a promising anti-tumour therapeutic tool over 18 months.